PROGRESSIVE'S EVENING STROLL DATE: 17 August, 2026

Market Snapshot:

Bears continued to dominate the market and dragged the Index below the recent low of 24,270. However, a bullish divergence helped the Index trim most of its losses, but towards the end, it erased recovery gains and eventually settled at 24,287.65 with a loss of 78.35 points. Among the sectors, Realty and Metal were the top performers, while IT and FMCG lagged. Mid- and small-cap stocks recovered from lower levels and ended in positive territory, outperforming the Benchmark Index.

HOW THE DAY TRENDED

INDICES			
Index	**Close**	**Points**	**%Chg.**
Sensex	77728.16	(281.09)	**(0.36)**
Nifty50	24287.65	(78.35)	**(0.32)**
Nifty Midcap 100	63817.00	34.85	**0.05**
Nifty Small Cap 100	19809.5	70.70	**0.36**

SECTORAL GAINERS / LOSERS			
Sectors	**Close**	**Points**	**%Chg.**
NIFTY REALTY	908.70	13.05	**1.46**
NIFTY METAL	13104.60	162.90	**1.26**
NIFTY FMCG	48105.05	(510.00)	**(1.05)**
NIFTY IT	30807.80	(549.95)	**(1.75)**

NIFTY TOP GAINERS / LOSERS					
Gainers	**CMP (Rs)**	**%Chg.**	**Losers**	**CMP (Rs)**	**%Chg.**
HINDALCO	1049.90	**1.98**	HCL TECH	1325.00	**(2.57)**
TATA STEEL	186.00	**1.36**	INFY	1139.90	**(2.51)**
HDFC LIFE	543.00	**1.33**	SUN PHARMA	1882.00	**(2.49)**
ONGC	238.49	**0.88**	TCS	2313.20	**(2.02)**

INDICES LEVELS FOR August 18, 2026

Nifty (future)	
Resistance	24500
Support	24290

Bank Nifty (future)	
Resistance	58100
Support	57360

PROGRESSIVE'S EVENING STROLL **DATE: 17 August, 2026**

KEY TAKEAWAYS OF THE DAY

♦ **Reliance Industries and Rolls-Royce in partnership for AMCA fighter jet engines:**

The company announced its strategic intent to partner with British aerospace major Rolls-Royce to develop India's indigenous combat engine for the Advanced Medium Combat Aircraft (AMCA) programme. The partnership will offer capabilities for the design, development, manufacturing and delivery of the combat engine. As part of the partnership, both companies will explore the formation of a dedicated aerospace gas turbine complex which will be a centre of excellence for power and propulsion technology in India.

♦ **Four USFDA observations received for Dr Reddy's Hyderabad plant:**

The USFDA completed a GMP inspection at the company's formulations manufacturing facility (FTO-3) in Bachupally, Hyderabad. The inspection was conducted from August 6 to August 14, 2026. The USFDA issued a Form 483 containing four observations following the inspection of the manufacturing facility in Bachupally.

♦ **Texmaco Rail brings in investor for defence business with up to Rs2000mn funding:**

The company has executed a Share Subscription and Shareholders' Agreement (SSSA) with its subsidiary, Texmaco Defence Technologies (TDTL), and Vagus Def Tech & Aerospace Fund-1 (Calculus) for an investment of up to Rs200cr. The first Rs100cr will be invested by subscribing to a fresh issue of equity shares, while the remaining Rs100cr will be invested through the issuance of equity or debt instruments. Following the proposed subscription, Calculus will hold 30% of the equity share capital of TDTL, and TDTL will cease to be a wholly owned subsidiary of the company.

♦ **HAL partners with Adani defence systems and BEML for production of Light Combat Helicopter:**

Hindustan Aeronautics Limited has partnered with Adani Defence and BEML. These agreements will boost indigenous helicopter production capabilities significantly. BEML will manufacture forty-eight fuselage structures for the Prachand helicopter. Adani Defence will produce forty-two fuselage structures under this new partnership. This collaboration strengthens India's aerospace manufacturing ecosystem and supply chain.

♦ **Sun Pharma wins US Lipitor antitrust appeal, closing case:**

Sun Pharmaceutical Industries secured a significant legal victory as the Third Circuit Court of Appeals upheld summary judgment in its favor in the Lipitor (Atorvastatin) antitrust case, also denying class certification to plaintiffs. The litigation stemmed from a 2008 patent settlement between Sun Pharma and Pfizer, with plaintiffs alleging unlawful delay of generic competition. The matter is now considered substantially closed.

Source: Media Reports

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-:

· PSBPL or its associates financial interest in the subject company: NO

· Research Analyst (s) or his/her relative's financial interest in the subject company: NO

· PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.

· PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.

· The research analyst has served as officer, director or employee of the subject company: NO

· Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read “Risk Disclosure Document for Capital Market and Derivatives Segments” as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,

122-124, Laxmi Plaza, Laxmi Indl Estate,

New Link Rd, Andheri West,

Mumbai—400053, Maharashtra

www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Mamatha Poojari,

Email: compliance@progressiveshares.com,

Contact No.:022-40777500.

Grievance Officer:
Email: grievancecell@progressiveshares.com